Change from baseline in primary and selected secondary end-points with bosentan and placebo in the Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension (BENEFiT) study

Co-primary end-points
 6MWD m73344.5 (325.2–363.8)0.8 (–18.1–19.7)67340.0 (319.2–360.8)2.9 (–12.9–18.8)0.5449
 PVR dyn·s·cm–571787 (708–866)30 (–25–85)66778 (698–857)–146 (–207– –85)<0.0001
Selected secondary end-points
 NT-proBNP ng·L−1761405721481–622 (–1018– –225)0.0034
 WHO-FC II/III/IV8022/56/211.3% moved to lower class; 8.8% moved to higher class7622/51/314.5% moved to lower class; 2.6% moved to higher classns
  • Data are presented as n or mean (95% confidence interval), unless otherwise stated. 6MWD: 6-min walking distance; PVR: pulmonary vascular resistance; NT-proBNP: N-terminal pro-brain natriuretic peptide; WHO-FC: World Health Organization functional class; ns: nonsignificant. #: calculated with the use of stratified Wilcoxon test for the change from baseline and the Wilcoxon rank sum test for treatment effect; : data for treatment effect, not change from baseline. Data from [41].